What are the odds of being harmed by not reading drug labels or mixing medications?
Evidence quality 4.63/5
Eight-dimension review score against the quality rubric . Each dimension scored 1–5.
- D1 Source grounding
- 5/5
- D2 Source authority
- 5/5
- D3 Arithmetic
- 5/5
- D4 Uncertainty
- 4/5
- D5 Scope
- 4/5
- D6 Prose
- 5/5
- D7 Perception honesty
- 4/5
- D8 Caveat completeness
- 5/5
Lifetime probability · lifetime, US adult
1 in 35
2.8% lifetime chance
Most people underestimate this.
range 1 in 59 to 1 in 22
● your factors — click this risk ▾ to reveal
≈ As likely as
Perceived
No standing survey isolates public perception of harm from medication non-adherence or drug-drug interactions as a discrete fear. Most adults file drug-label compliance under "common sense I already follow," which is precisely the problem: CDC data show that roughly half of patients with chronic conditions do not take medications as directed, yet almost none of them would describe themselves as at elevated risk. Polypharmacy interactions occupy an even deeper blind spot. The average reader knows vaguely that "grapefruit and statins" is a thing, but cannot name the mechanism (CYP3A4 inhibition) or estimate the magnitude (up to 260% elevation in simvastatin blood levels). The gap between that hazy awareness and the 125,000 deaths attributed annually to non-adherence alone is one of the wider perception mismatches in the medication-risk space.
Rough estimate: Most adults would place their lifetime risk of serious harm from medication misuse well below 1 in 100
Source: editorial intuition, not polled
Actual
~125,000 US deaths/year from non-adherence; ~1.5 million ER visits/year for adverse drug events; ~99,628 emergency hospitalisations/year in adults 65+
US adults, all ages
Show derivation
The 125,000 deaths/year figure is the widely cited estimate for US deaths attributable to medication non-adherence, drawn from Osterberg & Blaschke (NEJM 2005) and corroborated by the Annals of Internal Medicine and CDC medication-safety literature. Against a US adult population of ~258 million, this gives a per-adult-year hazard of ~4.84 x 10^-4. Compounded over 59 years of remaining adult life (from age 18): 1 - (1 - 0.000484)^59 ≈ 0.0282, or roughly 1 in 35. This figure encompasses deaths from non-adherence (skipped doses, premature discontinuation), incorrect dosing (not reading labels), and drug-drug/drug-food interactions (polypharmacy, grapefruit- statin, warfarin-vitamin K). It deliberately excludes intentional overdose, which is tracked under drug-overdose. The number is conservative in one direction (many non-adherence deaths are attributed to the underlying disease rather than the treatment failure) and aggressive in another (the 125,000 figure has been contested as poorly sourced). The uncertainty band reflects this methodological spread.
Caveats: The 125,000 deaths/year figure for medication non-adherence is widely cited but …
The 125,000 deaths/year figure for medication non-adherence is widely cited but poorly sourced at its origin — it traces to a chain of secondary citations rather than a single definitive primary study, and the true number may be anywhere from 75,000 to 200,000 depending on how strictly "non-adherence death" is defined. The entry deliberately uses the 125,000 midpoint and places a wide uncertainty band around the lifetime figure. This entry covers harm from misuse (wrong dose, skipped dose, unrecognised interaction) of medications taken with therapeutic intent; it does not cover intentional overdose or recreational drug misuse, which are tracked under drug-overdose. The grapefruit-statin and warfarin-vitamin K examples are illustrative of the interaction mechanism, not the primary drivers of mortality — anticoagulant dosing errors and insulin errors are the bigger killers in the Budnitz data. Readers on a single medication with no comorbidities face a risk well below the headline; readers on complex multi-drug regimens face a risk several multiples above it.
Risks at similar odds
Other risks with roughly the same likelihood — useful for calibration.
Medication reaction
What are the odds of a serious adverse drug reaction from prescribed medication?
High-heel ER visit
What are the odds of an emergency-room visit from a high-heel-related injury over a lifetime of wearing heels?
Benzo dependence
What are the odds of developing benzodiazepine dependence after a standard prescription?
Recently viewed on this device
Stored locally — clear anytime.
Pick challenger
The numbers on medication misuse hide in plain sight. CDC surveillance counts more than 1.5 million emergency department visits and nearly 500,000 hospitalisations per year in the United States for adverse drug events, and the medication non-adherence literature attributes roughly 125,000 deaths annually to patients not taking medications as directed — skipped doses, premature discontinuation, unrecognised interactions, and simple failure to read the label. Budnitz et al., writing in the New England Journal of Medicine in 2011, found that among adults 65 and older alone there were an estimated 99,628 emergency hospitalisations per year for adverse drug events, with nearly two thirds caused by unintentional overdoses of just four drug classes: warfarin, insulin, oral antiplatelet agents, and oral hypoglycaemics. These are not exotic medications or rare idiosyncratic reactions. They are the most commonly prescribed drugs in the country, taken incorrectly by patients who did not understand the dosing, did not check for interactions, or simply stopped paying attention.
The interaction problem compounds the non-adherence problem in a way that escapes intuition. A patient on warfarin who increases vitamin K intake from leafy greens can swing their INR into a bleeding-risk zone within days. A patient on simvastatin who drinks grapefruit juice can elevate blood levels of the drug by 260%, enough to trigger rhabdomyolysis. The FDA maintains an explicit consumer warning about grapefruit interactions with statins, calcium channel blockers, and immunosuppressants, but the warning reaches a small fraction of the patients who need it. Polypharmacy — defined as five or more concurrent medications — is the structural accelerant: drug-drug interaction risk scales non-linearly with the number of agents, and roughly 40% of US adults over 65 meet the polypharmacy threshold. The Budnitz finding that nearly half of ADE hospitalisations fell on adults 80 and older is not a coincidence; it is the predictable output of a system that gives elderly patients complex regimens and minimal pharmacist oversight.
The perception gap on this fear runs in one direction: downward. Most adults would not place “didn’t read the drug label” anywhere near their top-ten health risks, and essentially none would estimate their lifetime probability of fatal medication misuse at 1 in 35. That number is higher than the lifetime odds of dying in a car crash (1 in 93) and comparable to the lifetime odds of a fatal adverse drug reaction from medications taken correctly (1 in 58 on the medication-serious-adverse-event entry). The difference is that misuse deaths are, by definition, preventable: reading the label, checking interactions, and maintaining adherence to prescribed regimens would eliminate the majority of them. The barrier is not pharmacology. It is attention.
Claim ledger
Every number below is what each source reported, with the verbatim quote we relied on and how we arrived at our figure. Click any link to verify directly.
-
[1] New England Journal of Medicine / Budnitz DS, Lovegrove MC, Shehab N, Richards CL — Emergency Hospitalizations for Adverse Drug Events in Older Americans
Emergency Hospitalizations for Adverse Drug Events in Older Americans- Statistic
An estimated 99,628 emergency hospitalisations per year for adverse drug events in US adults aged 65+, 2007-2009; nearly two thirds due to unintentional overdoses; warfarin, insulin, oral antiplatelet agents, and oral hypoglycaemic agents most commonly implicated- Excerpt
“"There were an estimated 99,628 emergency hospitalizations (95% confidence interval [CI], 55,531 to 143,724) for adverse drug events in U.S. adults 65 years of age or older each year from 2007 through 2009. Nearly half of these hospitalizations were among adults 80 years of age or older (48.1%)." ”
- Source data from
- 2011-11-24
- Accessed
- 2026-04-18 · archived copy
- Calculation
- Budnitz et al. used nationally representative NEISS-CADES data to estimate ~99,628 annual emergency hospitalisations for ADEs in adults 65+. Nearly two thirds (65.7%) were due to unintentional overdoses — i.e., dosing errors or failure to read labels correctly — rather than idiosyncratic reactions. The four most commonly implicated drug classes (warfarin, insulin, oral antiplatelets, oral hypoglycaemics) are precisely the medications where label-reading and interaction awareness matter most. This study anchors the "older adult" slice of the entry and validates the claim that label misuse and interaction ignorance, not exotic side-effects, drive the bulk of ADE hospitalisations.
- Independence
- Independent of the CDC FastStats aggregate and the Osterberg non-adherence mortality estimate. Uses the same NEISS-CADES surveillance platform as CDC FastStats but reports a distinct age-stratified analysis from a different time window.
-
[2] Centers for Disease Control and Prevention (CDC) — FastStats: Medication Safety Data
FastStats: Medication Safety DataSee all 2 Likelier entries citing this source →
- Statistic
More than 1.5 million US ED visits per year for adverse drug events; almost 500,000 require hospitalisation; adults 65+ account for more than 600,000 ED visits- Excerpt
“"More than 1.5 million people visit emergency departments for ADEs each year in the United States, and almost 500,000 require hospitalization. Older adults (65 years or older) visit emergency departments more than 600,000 times each year, more than twice as often as younger people." ”
- Source data from
- 2024-05-01
- Accessed
- 2026-04-18 · archived copy
- Calculation
- CDC's aggregate ADE surveillance provides the contemporary US denominator. Of the ~1.5 million annual ED visits, a substantial fraction involve medication misuse (wrong dose, missed dose, drug interaction) rather than idiosyncratic reactions to correctly taken medications. The 500,000 hospitalisations/year figure is the basis for the non-fatal serious-harm estimate. Combined with the 125,000 deaths/year non-adherence figure, it implies roughly 375,000 hospitalisations/year result in recovery — consistent with the overall case-fatality rate in the ADE literature.
- Independence
- CDC FastStats is the authoritative US national surveillance estimate. It shares the NEISS-CADES platform with Budnitz et al. but reports a broader age range and more recent time window.
-
[3] The Permanente Journal / Kleinsinger F — The Unmet Challenge of Medication Nonadherence
The Unmet Challenge of Medication Nonadherence- Statistic
Medication non-adherence causes approximately 125,000 preventable deaths and $100 billion in preventable medical costs annually in the US; 40-50% of patients with chronic diseases do not adhere to prescribed regimens- Excerpt
“"Nonadherence is thought to cause at least 100,000 preventable deaths and $100 billion in preventable medical costs per year." ”
- Source data from
- 2018-06-01
- Accessed
- 2026-04-18 · archived copy
- Calculation
- Kleinsinger's review synthesises the medication non-adherence literature and reports the 100,000-125,000 deaths/year figure that anchors this entry's native numerator. The 40-50% chronic-disease non-adherence rate is the behavioural denominator: roughly half of all adults on long-term medications are not taking them as directed, and a fraction of those non-adherent patients die from the resulting treatment failure. The $100 billion cost estimate is not used in the probability calculation but contextualises the scale of the problem.
- Independence
- Kleinsinger is a narrative review synthesising prior primary studies (including Osterberg & Blaschke NEJM 2005 and others). It is not independent of those upstream estimates but provides the most accessible modern summary of the 125,000 figure.
-
[4] U.S. Food and Drug Administration (FDA) — Grapefruit Juice and Some Drugs Don't Mix
Grapefruit Juice and Some Drugs Don't Mix- Statistic
Grapefruit can increase blood levels of certain statins (simvastatin, atorvastatin) by inhibiting CYP3A4; one study found a 260% increase in simvastatin blood levels with grapefruit juice- Excerpt
“"Grapefruit juice can cause the body to metabolize drugs abnormally, resulting in higher or lower levels of the drug in the blood. When there is too much drug in the blood, you may have more side effects." ”
- Source data from
- 2021-07-01
- Accessed
- 2026-04-18 · archived copy
- Calculation
- The FDA consumer update documents the CYP3A4-mediated grapefruit-statin interaction mechanism that is the canonical example of a food-drug interaction in this entry. The 260% simvastatin blood-level increase is the headline figure used to illustrate how a common food can turn a safe medication into a dangerous one. This source is used for the drug-interaction narrative, not for the headline mortality calculation.
- Independence
- Independent of the CDC and Budnitz sources. FDA consumer guidance based on pharmacokinetic studies, not epidemiological surveillance.